OncoZenge AB (publ)
STO: ONCOZ.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stian Kildal
- Employees
- 1
- Headquarters
- Bromma, Sweden
- IPO year
- 2021
- Market cap
- SEK 80.8M
- Website
- https://www.oncozenge.se
Loading ONCOZ…
Loading profile data…Frequently asked questions about ONCOZ
What does OncoZenge AB (publ) (ONCOZ.ST) do?
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
Where does ONCOZ.ST trade?
OncoZenge AB (publ) (ONCOZ.ST) trades on the Stockholm Stock Exchange.
What sector is ONCOZ.ST in?
OncoZenge AB (publ) (ONCOZ.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OncoZenge AB (publ)?
Stian Kildal is the chief executive officer of OncoZenge AB (publ) (ONCOZ.ST).
Where is OncoZenge AB (publ) headquartered?
OncoZenge AB (publ) is headquartered in Sweden.
Does ONCOZ.ST pay a dividend?
OncoZenge AB (publ) (ONCOZ.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ONCOZ.ST go public?
OncoZenge AB (publ) (ONCOZ.ST) completed its initial public offering in 2021.